IXICO plc provides data analytics services to the biopharmaceutical industry in the United States, the United Kingdom, Europe, and internationally. More Details
Flawless balance sheet and good value.
Share Price & News
How has IXICO's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IXI is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: IXI's weekly volatility has decreased from 10% to 5% over the past year.
7 Day Return
GB Life Sciences
1 Year Return
GB Life Sciences
Return vs Industry: IXI underperformed the UK Life Sciences industry which returned 13.6% over the past year.
Return vs Market: IXI underperformed the UK Market which returned 22.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is IXICO's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StDid Business Growth Power IXICO's (LON:IXI) Share Price Gain of 184%?
2 months ago | Simply Wall StAre Strong Financial Prospects The Force That Is Driving The Momentum In IXICO plc's LON:IXI) Stock?
3 months ago | Simply Wall StHere's Why I Think IXICO (LON:IXI) Is An Interesting Stock
Is IXICO undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: IXI (£0.7) is trading below our estimate of fair value (£1.91)
Significantly Below Fair Value: IXI is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: IXI is good value based on its PE Ratio (24.9x) compared to the UK Life Sciences industry average (61.8x).
PE vs Market: IXI is poor value based on its PE Ratio (24.9x) compared to the UK market (23.6x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IXI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IXI is good value based on its PB Ratio (3.2x) compared to the GB Life Sciences industry average (4.2x).
How is IXICO forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as IXICO has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has IXICO performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IXI has a high level of non-cash earnings.
Growing Profit Margin: IXI's current net profit margins (13.3%) are higher than last year (8%).
Past Earnings Growth Analysis
Earnings Trend: IXI has become profitable over the past 5 years, growing earnings by 66.3% per year.
Accelerating Growth: IXI's earnings growth over the past year (90.6%) exceeds its 5-year average (66.3% per year).
Earnings vs Industry: IXI earnings growth over the past year (90.6%) exceeded the Life Sciences industry -8.5%.
Return on Equity
High ROE: IXI's Return on Equity (12.7%) is considered low.
How is IXICO's financial position?
Financial Position Analysis
Short Term Liabilities: IXI's short term assets (£10.5M) exceed its short term liabilities (£2.3M).
Long Term Liabilities: IXI's short term assets (£10.5M) exceed its long term liabilities (£707.0K).
Debt to Equity History and Analysis
Debt Level: IXI is debt free.
Reducing Debt: IXI has not had any debt for past 5 years.
Debt Coverage: IXI has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: IXI has no debt, therefore coverage of interest payments is not a concern.
What is IXICO current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IXI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IXI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IXI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IXI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IXI's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Giulio Cerroni (59 yo)
Mr. Giulio Cerroni has been Chief Executive Officer of IXICO Plc since February 6, 2017 and serves as its Director. Mr. Cerroni has almost 30 years of international management experience gained in life sci...
CEO Compensation Analysis
Compensation vs Market: Giulio's total compensation ($USD747.67K) is above average for companies of similar size in the UK market ($USD325.48K).
Compensation vs Earnings: Giulio's compensation has been consistent with company performance over the past year.
Experienced Management: IXI's management team is considered experienced (4.3 years average tenure).
Experienced Board: IXI's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.3%.
IXICO plc's company bio, employee growth, exchange listings and data sources
- Name: IXICO plc
- Ticker: IXI
- Exchange: AIM
- Founded: 1995
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£33.465m
- Shares outstanding: 48.15m
- Website: https://www.ixico.com
Number of Employees
- IXICO plc
- Griffin Court
- 4th Floor
- Greater London
- EC1A 9PN
- United Kingdom
IXICO plc provides data analytics services to the biopharmaceutical industry in the United States, the United Kingdom, Europe, and internationally. It provides collection, analysis, management, and reporti...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/07/31 04:32|
|End of Day Share Price||2021/07/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.